Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Brian Orelli, The Motley Fool - Motley Fool - Sat May 16, 10:04AM CDT
Orexigen Therapeutics has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals and VIVUS weren't able to do: keep its share price above where it was when its weight-loss drug was approved in September. ...
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 198.37 (+3.87), VRTX: 127.31 (+1.10), OVAS: 30.01 (+0.84), MYL: 71.38 (+0.71), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), ALR: 50.79 (+0.04), ONTY: 2.59 (+0.16), CELG: 116.37 (+0.84), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), OREX: 4.98 (-0.03), FCSC: 3.92 (-0.10), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), GWPH: 112.93 (+0.68), CTSO: 6.24 (+0.31), ACHN: 11.03 (+1.46), RMD: 56.81 (+0.61), SNY: 50.40 (-0.12), PBYI: 181.30 (+4.29)
Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT
PFE: 33.98 (-0.01), AZN: 68.74 (-0.55), LLY: 72.94 (+0.04), SNY: 50.40 (-0.12)
How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 4.98 (-0.03)
Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT
OREX: 4.98 (-0.03)
First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT
Infinity Pharmaceuticals: Analyzing The Impact Of Repurchasing Takeda's Royalty Agreement
Jonathan Liu - at Seeking Alpha - Mon Apr 13, 7:50PM CDT
INFI: 12.92 (+0.62), ABBV: 65.61 (-0.38)
Takeda Pharma offers $2.2B to settle Actos cases
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:31AM CDT
LLY: 72.94 (+0.04)
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT
ABBV: 65.61 (-0.38), INFI: 12.92 (+0.62)
Why ImmunoGen Inc. is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 23, 2:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. ImmunoGen, What's happening: Shares in ...
IMGN: 8.67 (+0.08), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04)
Takeda licenses ImmunoGen's ADC technology to develop cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 6:47AM CDT
IMGN: 8.67 (+0.08)
Orexigen torpedoes shorts on news of Contrave's heart safety benefit
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 12:03PM CST
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
Amgen's Kyprolis beats Takeda's Velcade in head-to-head study
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 10:53PM CST
AMGN: 163.44 (+1.08)
Heptares Takes Sosei Out Of Its Comfort Zone
EP Vantage - Seeking Alpha - Mon Feb 23, 2:37PM CST
It makes perfect sense for a small Japanese company to harbour expansion plans, but the private UK neuroscience player Heptares Therapeutics makes an unusual bedfellow for Sosei ( OTC:SOLTF ) , a group with a predominantly respiratory focus....
AZN: 68.74 (-0.55), NVS: 104.06 (+0.31)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST
SCMP: 16.04 (+0.10)
AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST
AMAG: 65.33 (+3.36)
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 40.50 (+0.56), AZN: 68.74 (-0.55), MRK: 60.01 (-0.22), BMY: 68.00 (+0.36), CELG: 116.37 (+0.84), FPRX: 21.32 (+0.21)
Takeda's ixazomib a Breakthrough Therapy for amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:26AM CST
GE Healthcare and Takeda team up in liver disease R&D
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:22AM CST